CriticalAntiretroviral, HIV protease inhibitor×Antianginal – late sodium current inhibitor
Updated · Methodology
Mechanism
The liver and gut break down ranolazine mainly through the enzyme CYP3A4 and to a lesser extent through CYP2D6, and CYP3A4 inhibitors raise its levels (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA; ranolazine label, US Food and Drug Administration, FDA). In the liver, CYP3A4 also metabolises atazanavir, and atazanavir inhibits this enzyme (atazanavir SmPC, EMA). In Europe atazanavir is taken with ritonavir, which inhibits CYP3A4 more strongly than atazanavir, or as a fixed-dose combination with cobicistat, a strong CYP3A inhibitor (atazanavir and atazanavir/cobicistat SmPCs, EMA). The documents give no figures for this pair. For comparison, the strong inhibitor ketoconazole increased the area under the concentration-time curve (AUC) of ranolazine 3.0- to 3.9-fold (ranolazine SmPC, EMA). The higher the ranolazine level, the more frequent its dose-dependent adverse effects, such as nausea and dizziness, and the greater the prolongation of the heart-rate-corrected QT interval (QTc) (EMA).
Symptoms
Dizziness, nausea and vomiting become more frequent as the ranolazine dose rises (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). Abnormal coordination, myoclonus, paraesthesia and tremor have also been reported, often starting after an increase in ranolazine dose or exposure (ranolazine label, US Food and Drug Administration, FDA). QT prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG), but feeling faint or lightheaded and an irregular or fast heartbeat may be related to it (FDA). Atazanavir itself prolongs the PR interval on the ECG, usually without symptoms and generally limited to first-degree atrioventricular block, but second-degree block has also been reported (atazanavir label, FDA).
Management
The combination is contraindicated. The European ranolazine summary of product characteristics (SmPC) contraindicates ranolazine with strong CYP3A4 inhibitors and names human immunodeficiency virus (HIV) protease inhibitors among the examples (ranolazine SmPC, European Medicines Agency, EMA). According to its own SmPC, atazanavir is an HIV protease inhibitor (atazanavir SmPC, EMA). In Europe atazanavir is indicated with low-dose ritonavir. The SmPC does not recommend withdrawing ritonavir and allows it only under restricted conditions (atazanavir SmPC, EMA). Before starting atazanavir with ritonavir, consult the ritonavir SmPC (atazanavir SmPC, EMA), which contraindicates ranolazine (ritonavir SmPC, EMA). The US ranolazine label also lists ritonavir among the strong CYP3A inhibitors that must not be used with ranolazine (ranolazine label, US Food and Drug Administration, FDA). The atazanavir documents do not name ranolazine, but they call for special precautions when atazanavir is given with drugs that can prolong the QT interval (EMA). Ranolazine prolongs the heart-rate-corrected QT interval (QTc) in a dose-dependent way (ranolazine SmPC, EMA). If the two drugs have nevertheless been taken together and signs of ranolazine overdose appear, monitor the patient closely and give symptomatic and supportive treatment (EMA). Continuous electrocardiogram (ECG) monitoring may be needed (FDA). Haemodialysis is unlikely to remove ranolazine completely, because about 62% of it is bound to plasma proteins (EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ranolazine extended-release tablets (Zydus Lifesciences) – prescribing information (2026)– FDA label, Zydus Lifesciences, DailyMed setid d74f3dea-7357-4e9a-be9a-2f498a44108a, version 5, 09/2026, sections 2.2, 4, 5.1, 7.1 and 7.2
- FDA: Reyataz (atazanavir) prescribing information (2024)– DailyMed setid 165cff62-b284-4a27-a65d-9ec8a5bfcdd8, revisión 12/2024, secciones 4 y 7.3
- EMA: Ficha técnica: Ritonavir (EU/1/96/016), sección 4.3 (2026)– EMA, Norvir, ficha técnica en CIMA (nº registro 96016005), consultada 03.10.2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Ranolazina (EU/1/08/462), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 08462001 (EU/1/08/462), secciones 4.3, 4.5 y 4.9, consultado 10/2026
- EMA: Ficha técnica: Atazanavir/cobicistat (EU/1/15/1025), sección 4.5 (2026)– EMA, Evotaz 300 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, secciones 4.3 y 4.5
- EMA: Ficha técnica: Atazanavir, Reyataz (EU/1/03/267), sección 4.3 (2026)– EMA, Reyataz 300 mg cápsulas (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 03267008, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Ranolazina, Ranexa (EU/1/08/462), sección 4.4 (2026)– EMA, Ranexa 375 mg comprimidos de liberación prolongada (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08462001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.1, 4.4 y 4.5